Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Minimizing toxicity while maximizing efficacy is a goal that has proven challenging in patients who are considered high risk for relapse after allogeneic hematopoietic cell transplantation (HCT), particularly in older individuals. The median patient age at diagnosis of myelodysplastic syndromes (MDS) is in the early 70s [1] and for acute myeloid leukemia (AML) in the mid-to-late 60s (SEER statistics, 2005 to 2009), and typically reduced-intensity conditioning regimens are used in preparation for HCT.

Source: Biology of Blood and Marrow Transplantation - December 20, 2017 Category: Hematology Authors: H. Joachim Deeg, Emily A. Stevens, Rachel B. Salit, Ralph P. Ermoian, Min Fang, Boglarka Gyurkocza, Mohamed L. Sorror, Giancarlo Fatobene, Joachim Baumgart, Lauri M. Burroughs, Colleen Delaney, Kris Doney, Daniel N. Egan, Mary E.D. Flowers, Filippo Milano Source Type: research